The Foundation for the National Institutes of Health (FNIH) announced last week that it has received a donation of more than $14 million to launch the third phase of the Alzheimer’s Disease Neuroimaging Initiative, or ADNI3, a study aimed at identifying biomarkers from brain scans, genetics, blood, and cerebrospinal fluid (CSF) to detect the progression of Alzheimer’s disease.
The donation comes from a united effort among several patient advocacy groups, private foundations, industry, and individual donors dedicated to helping make a difference in the field of Alzheimer’s research.
“Additions to the third phase of ADNI include recruiting 1,200 volunteers to join about 800 current participants to enrich the existing dataset, using state-of-the-art imaging techniques to monitor brain levels of tau, a protein that is often abnormal in Alzheimer’s patients, and performing cutting-edge analyses to assess complex interactions between the brain and body,” according to the official FNIH press release. “ADNI3 also will assess cognitive function through computer tests at home and in the doctor’s office and measure changes in subjects’ ability to handle money, which can be a warning sign of the disease.”
The University of Pennsylvania’s John Q. Trojanowski, MD, PhD, director of the Institute on Aging and professor of Pathology and Laboratory Medicine, and Leslie M. Shaw, PhD, professor of Pathology and Laboratory Medicine, are heavily involved in ADNI and co-direct its Biomarker Core.
“This phase of ADNI will bring us close to defining highly informative AD biomarkers for the diagnosis of AD even before its clinical onset, thereby making it possible to conduct prevention trials of therapies that could arrest the AD process in presymptomatic individuals even before AD begins to manifest clinically in patients,” said Dr. Trojanowski. “We are so grateful to the donors who have helped make this possible.”
In addition to banking biofluids from their unique cohort of subjects, the Biomarker Core also conducts studies including those to identify new biomarkers and species of tau and a-beta in CSF and plasma.
Dr. Shaw explained “the ADNI3 study enables us to build on the progress of validation and standardization of AD biomarker tests that detect neuropathologic hallmarks of the disease and track disease progression over years of time within individual study subjects. As a result of the generous support of donors to the ADNI3 study, this work now continues and we expect to see these tests used to determine subject eligibility in therapeutic trials at all stages of the disease and to reflect therapeutic effects.”
To learn more about ADNI, visit: http://www.adni-info.org